People

 

Vicki Nienanber
President and CSO
 
Dr. Vicki Nienaber has been a leader in the fragment-based drug discovery field since its inception at Abbott laboratories during the 1990's.  At Abbott, she worked alongside NMR screeners pairing SARbyNMR with x-ray for drug discovery and is primary inventor of the first crystallographic screening method still in use today.

 

Dr. Nienaber has led numerous programs including SGX collaborations with Eli Lilly, Novartis and SGX internal FBLD pipeline. Dr. Nienaber also built the fragment screening platform at Abbott laboratories including invention of the first crystal mounting robot (ACTOR, now marketed by Rigaku). She also fully implimented the structural biology platform at SGX coordinating between engineers, programmers and scientists.

 

Publication list at NCBI:  http://www.ncbi.nlm.nih.gov/sites/myncbi/vicki.nienaber.1/bibliography/40535764/public/?sort=date&direction=ascending

Erika Zehm
Marketing and Communications


Ms. Zehm has been a member of the Zenobia team since 2009. Before coming to Zenobia, She worked at the non-profit, Freedom is not Free, supporting families of veterans impacted by the wars in the middle east.

 

At Zenobia, Ms. Zehm has been responsible for all of the marketing and communcations surrounding the Zenobia Fragments product line.

Academic and quantity discounts available. 

Contact us if you are working on COVID-19.

© 2015 by Zenobia Therapeutics Inc